Peer-reviewing clinical trial data is a basic biotech requirement to medical community and investors. Many failed biotechs did it. It is not great value -- it normally has little share price impact. It is a reconfirmation of the clinical data, nothing more.
Doesn't help approvals or any other benefit for shareholders.
Market Data 
Markets 
AI
